🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementJoint pain improvement vs new joint pain — November 2025

Joint pain improvement vs new joint pain — November 2025

NurseLeah_Nash Sat, Nov 23, 2024 at 7:32 PM 11 replies 1,825 viewsPage 1 of 3
This thread is more than 18 months old. Information may be outdated. Consider searching for more recent discussions.
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Nov 23, 2024 at 7:32 PM#1

The nausea I get is not really nausea, it is an aversion. Food I want in the abstract becomes repellent in front of me, which no side-effect list describes.

Trial-level incidence runs roughly 20 to 25% for nausea at the higher dose tiers and 12 to 17% for diarrhoea, with most events mild to moderate and concentrated in the weeks after each escalation.

What I actually want to know is what distinguishes the nausea you can titrate through from the nausea that means stop.

I would rather have one careful answer than five confident ones.

44 14RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 41 others
Reply Quote Save Share Report
sarah.morrison
VIP Member
3,212
14,567
Jan 2024
California
Online
Nov 23, 2024 at 9:56 PM#2

Short answer first, then the reasoning. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

Last edited: Nov 23, 2024 at 10:56 PM
43 13roxy_nash, tony_orlando, Dr.NephBHM_UK and 40 others
Reply Quote Save Share Report
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Nov 24, 2024 at 12:20 AM#3
sarah.morrison said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

No disagreement with sarah.morrison. One condition attached. The meal advice is right and incomplete without the hydration point. People stop drinking because drinking makes them feel full, then attribute dehydration symptoms to the drug.

Ask again with the specifics and you will get a better answer than this one.

42 12WendyG_ATL, SaraMom3, Dr.MetabolicMD and 39 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
ingrid_STO
Member
345
1,456
Jul 2024
Stockholm, SE
Nov 24, 2024 at 2:44 AM#4
NurseLeah_Nash said:
The nausea I get is not really nausea, it is an aversion.

Can confirm the pattern NurseLeah_Nash describes. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: Nov 24, 2024 at 5:44 AM
41 11InsuranceTom, WendyG_ATL, SaraMom3 and 38 others
Reply Quote Save Share Report
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Nov 24, 2024 at 5:03 PM#5

Clinical perspective, offered as context rather than as advice. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

40 10rachel_ABQ, traveltech_sara, AttorneyGrant and 37 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register